Journal of Cancer Therapy

Vol.2 No.5(2011), Paper ID 16618, 7 pages

DOI:10.4236/jct.2011.25095

 

Comparison of 4-Weekly vs 3-Weekly Gemcitabine as Adjuvant Chemotherapy Following Curative Resection for Biliary Tract Cancer: A Prospective Randomized Controlled Trial

 

Shogo Kobayashi, Atsushi Miyamoto, Junzo Shimizu, Masaki Kashiwazaki, Yutaka Takeda, Shigeyuki Ueshima, Yongkook Kim, Toru Kitagawa, Keizo Dono, Masaki Mori, Yuichiro Doki, Hiroaki Nagano

 

 

Copyright © 2011 Shogo Kobayashi, Atsushi Miyamoto, Junzo Shimizu, Masaki Kashiwazaki, Yutaka Takeda, Shigeyuki Ueshima, Yongkook Kim, Toru Kitagawa, Keizo Dono, Masaki Mori, Yuichiro Doki, Hiroaki Nagano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


S. Kobayashi, A. Miyamoto, J. Shimizu, M. Kashiwazaki, Y. Takeda, S. Ueshima, Y. Kim, T. Kitagawa, K. Dono, M. Mori, Y. Doki and H. Nagano, "Comparison of 4-Weekly vs 3-Weekly Gemcitabine as Adjuvant Chemotherapy Following Curative Resection for Biliary Tract Cancer: A Prospective Randomized Controlled Trial," Journal of Cancer Therapy, Vol. 2 No. 5, 2011, pp. 703-709. doi: 10.4236/jct.2011.25095.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.